Cybin Inc. Common Stock (HELP) Fundamentals 2026 — Revenue Analysis | SniperIQ
Cybin Inc. Common Stock (HELP) is a CA-listed Healthcare company in Biotechnology with a market capitalization of $403M, trading at $8.05 on the NASDAQ. This SniperIQ fundamentals page covers Cybin Inc. Common Stock's valuation, profitability (net margin 0.0%), revenue (-$45M in FY2026), balance-sheet quality, and AI signal context — from live market data, research only.
Full research coverage
- 8-Quarter Revenue & Margin Trend
- Debt Maturity & Coverage
- Peer Valuation Comparison
- Free Cash Flow & Owner Earnings
- AI Signal + Institutional Flow
- DCF Valuation Model
Frequently Asked Questions
What is Cybin Inc. Common Stock's market cap?
Cybin Inc. Common Stock (HELP) has a market capitalization of approximately $403M, trading at $8.05 on the NASDAQ. Market cap moves with the live share price.
What is Cybin Inc. Common Stock's P/E ratio?
Cybin Inc. Common Stock's trailing twelve-month P/E ratio is not meaningful (negative or nil earnings), with a price-to-book (P/B) of 1.7x. Valuation multiples are best compared with Healthcare sector peers rather than read in isolation.
How profitable is Cybin Inc. Common Stock?
Cybin Inc. Common Stock runs a net profit margin of 0.0%, a gross margin of 0.0%, and an operating margin of 0.0%. Margins and ROE indicate how efficiently the business converts sales into profit and shareholder returns.
How much revenue does Cybin Inc. Common Stock generate?
Cybin Inc. Common Stock reported revenue of -$45M for fiscal year 2026, with net income of -
Does Cybin Inc. Common Stock pay a dividend?
Cybin Inc. Common Stock does not currently show a material trailing dividend yield; it is positioned more as a total-return name. Always confirm the latest dividend policy in the company's filings.
Is Cybin Inc. Common Stock financially healthy?
Cybin Inc. Common Stock carries a debt-to-equity ratio of 0.00x and a current ratio of 9.52x, with a market beta of 0.62. Lower leverage and a current ratio above 1.0 generally signal a stronger balance sheet.
Is Cybin Inc. Common Stock a good stock to buy in 2026?
SniperIQ provides research-only market intelligence, not personalised financial advice or a buy/sell call. For Cybin Inc. Common Stock (HELP) the key facts are: market cap $403M, revenue -$45M, 52-week range 3.76-9.12. Weigh valuation, profitability, growth, and balance-sheet strength against Healthcare peers and form your own view.
Track Cybin Inc. Common Stock's full fundamentals live
Get Cybin Inc. Common Stock's 8-quarter revenue and margin trend, peer comparison, DCF model, and AI signal on the SniperIQ research dashboard.